Literature DB >> 33849386

Reply letter regarding seroconversion of hepatitis B surface antigen in a successful long-term immune cohort.

Zhigang Zheng1,2, Qing-Lei Zeng1,2, Yi-Hua Zhou1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33849386      PMCID： PMC8475598          DOI： 10.1080/21645515.2021.1897488

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  9 in total

1.  HBV transmission from an occult carrier with five mutations in the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient.

Authors:  Nicola Coppola; Giovanna Loquercio; Gilda Tonziello; Rosa Azzaro; Mariantonietta Pisaturo; Gaetano Di Costanzo; Mario Starace; Giuseppe Pasquale; Carmela Cacciapuoti; Arnolfo Petruzziello
Journal:  J Clin Virol       Date:  2013-07-12       Impact factor: 3.168

2.  The long-term efficacy, 13-23 years, of a plasma-derived hepatitis B vaccine in highly endemic areas in China.

Authors:  Feng Wang; Liping Shen; Fuqiang Cui; Shuang Zhang; Hui Zheng; Yong Zhang; Xiaofeng Liang; Fuzhen Wang; Shengli Bi
Journal:  Vaccine       Date:  2015-04-02       Impact factor: 3.641

3.  Hepatitis B variant in Europe.

Authors:  A R Zanetti; E Tanzi; G Manzillo; G Maio; C Sbreglia; N Caporaso; H Thomas; A J Zuckerman
Journal:  Lancet       Date:  1988-11-12       Impact factor: 79.321

4.  [Long-term efficacy of infant hepatitis B immunization program].

Authors:  Jian Gong; Rong-cheng Li; Jin-ye Yang; Yan-ping Li; Xiu-rong Chen; Zhi-yi Xu; Chong-bai Liu; Hui-lin Cao; Kai Zhao; Dao-ming Ni
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2003-04

5.  [Variations of hepatitis B virus infection epidemic pattern after long-term HBV vaccine immunization].

Authors:  Li-Ping Shen; Jin-Ye Yang; Zhao-Jun Mo; Rong-Cheng Li; Yan-Ping Li; Zeng-Liang Wei; Yong-Hui Dong; Kai-Jiao Zhou; Shao-Chao Wei; Kong-Xiong Fang; Tao Yu; Wen-Ying Zhang; Yong Zhang; Sheng-Li Bi
Journal:  Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi       Date:  2007-09

6.  Requirement for further validation on the seroconversion of hepatitis B surface antigen in successful vaccinees.

Authors:  Qing-Lei Zeng; Yi-Hua Zhou
Journal:  Hum Vaccin Immunother       Date:  2021-05-14       Impact factor: 3.452

7.  Long-term effectiveness of plasma-derived hepatitis B vaccine 22-28 years after immunization in a hepatitis B virus endemic rural area: is an adult booster dose needed?

Authors:  H Li; G J Li; Q Y Chen; Z L Fang; X Y Wang; C Tan; Q L Yang; F Z Wang; F Wang; S Zhang; S L Bi; L P Shen
Journal:  Epidemiol Infect       Date:  2017-01-09       Impact factor: 4.434

8.  Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China.

Authors:  Fuqiang Cui; Lipin Shen; Li Li; Huaqing Wang; Fuzhen Wang; Shengli Bi; Jianhua Liu; Guomin Zhang; Feng Wang; Hui Zheng; Xiaojin Sun; Ning Miao; Zundong Yin; Zijian Feng; Xiaofeng Liang; Yu Wang
Journal:  Emerg Infect Dis       Date:  2017-05       Impact factor: 6.883

9.  Seroconversion of hepatitis B surface antigen among those with previously successful immune response in Southern China.

Authors:  Zhigang Zheng; Guojian Li; Fuhui Liao; Lujuan Zhang; Xueyan Wang; Zhongliao Fang; Qinyan Chen; Huabin Liu; Liping Hu
Journal:  Hum Vaccin Immunother       Date:  2020-09-22       Impact factor: 3.452
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.